Group 1 - The core viewpoint of the article highlights that Yidu Technology (02158) has demonstrated confidence in its intrinsic value through a series of share buybacks, totaling nearly 68 million HKD since the start of 2026's first buyback on January 26, completing 16 buybacks in less than a month [1][1][1] - The company repurchased 163,000 shares at approximately 6 HKD per share on February 20, costing over 970,000 HKD, marking its first buyback operation after the Spring Festival [1][1][1] Group 2 - The AI healthcare industry is currently experiencing a golden period of development, driven by both policy and market forces, with a comprehensive acceleration in commercialization [1][1][1] - The Chinese government has issued implementation opinions for the application development of "Artificial Intelligence + Healthcare," aiming to establish a number of clinical vertical large models by 2027 and achieve intelligent auxiliary diagnosis coverage in secondary hospitals by 2030 [1][1][1] - The market for AI healthcare in China is projected to grow from 8.8 billion CNY in 2023 to 315.7 billion CNY by 2033, with a compound annual growth rate of 43.1% according to Frost & Sullivan [1][1][1]

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月20日斥资97.78万港元回购16.3万股。 ...

FF305 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不 ...

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on February 16, spending HKD 2.389 million to repurchase 404,000 shares [1]

Core Viewpoint - The Hong Kong stock market has seen a continuous share buyback trend since 2026, with leading companies like Yidu Tech (02158) actively participating to demonstrate confidence in their intrinsic value and future development [1] Group 1: Share Buyback Activity - Yidu Tech announced a share buyback on February 16, repurchasing 404,000 shares at approximately HKD 5.91 per share, totaling nearly HKD 2.4 million [1] - This marks the 15th buyback since the beginning of 2026, with a cumulative expenditure of nearly HKD 67 million [1] - The buyback activity has been characterized by high frequency and steady intensity, with 15 buybacks completed in less than a month since the first buyback on January 26 [1] Group 2: Business Developments - Yidu Tech's recent collaboration with Huazhong University of Science and Technology's Tongji Hospital on a multimodal AI database project for gastrointestinal tumors has been selected for the Ministry of Industry and Information Technology's 2025 AI medical device innovation initiative [1] - The company's growth prospects have been recognized by institutions, with Citigroup maintaining a "Buy" rating and raising the target price to HKD 11 in February [1]

Group 1 - The core viewpoint of the article highlights the ongoing share buyback trend in the Hong Kong stock market since 2026, with leading companies like Yidu Tech (02158) actively participating to demonstrate confidence in their intrinsic value and future development [1] Group 2 - On February 16, Yidu Tech announced a share buyback of 404,000 shares at approximately HKD 5.91 per share, costing nearly HKD 2.4 million, marking its 15th buyback since 2026 and totaling close to HKD 67 million in expenditures [1] - The buyback activity of Yidu Tech is characterized by "high frequency and steady strength," having completed 15 buybacks in less than a month since the first buyback on January 26 [1] - Yidu Tech's business prospects have been positively impacted by recent developments, including the successful selection of a multimodal AI database project for gastrointestinal tumor diagnosis in collaboration with Huazhong University of Science and Technology [1] - Citigroup maintained a "buy" rating for Yidu Tech in February and raised its target price to HKD 11, reflecting institutional recognition of the company's growth potential [1]

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月16日该公司斥资238.9万港元回购40.4万股， 回购价格为每股5.77-6.00港元。 ...

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan on February 16, 2026, involving an expenditure of HKD 2.389 million to repurchase 404,000 shares [1] - The buyback price range is set between HKD 5.77 and HKD 6.00 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 ...

Group 1 - The core point of the article is that Dr. Xie Li has resigned as an executive director of Yidu Technology (02158) to focus more on personal matters, effective from February 13, 2026 [1] Group 2 - The announcement indicates a significant leadership change within the company, which may impact its strategic direction and operations [1] - The timing of the resignation suggests potential implications for the company's future initiatives and governance [1] - The company may need to address this leadership transition to maintain investor confidence and operational stability [1]